ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for PHAT

Stock NamePhathom Pharmaceuticals Inc
TickerPHAT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS71722W1071

Show aggregate PHAT holdings

News associated with PHAT

How The Pieces Add Up: FTKI Headed For $21
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-10 07:46:44
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of “Buy” by Brokerages
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has been given an average recommendation of “Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the […] - 2025-09-01 04:21:06
XTX Topco Ltd Invests $565,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
XTX Topco Ltd purchased a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 90,191 shares of the company’s stock, valued at approximately $565,000. Other institutional investors and hedge funds have also […] - 2025-08-07 05:32:50
Cwm LLC Grows Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Cwm LLC boosted its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 20,997.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,384 shares of the company’s stock after buying an additional 7,349 shares during the quarter. Cwm LLC’s holdings in Phathom Pharmaceuticals […] - 2025-08-04 05:13:01
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $17.50 Consensus Target Price from Brokerages
Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating […] - 2025-07-16 02:20:51
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 20.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 117,803 shares of the company’s stock after purchasing an additional 19,778 shares during the period. UBS AM a distinct […] - 2025-06-11 04:38:59
Phathom Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:PHAT)
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) was the target of some unusual options trading activity on Monday. Investors acquired 2,377 call options on the stock. This is an increase of approximately 134% compared to the average volume of 1,017 call options. Institutional Trading of Phathom Pharmaceuticals Several large investors have recently made changes […] - 2025-06-11 02:06:51
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Bought by Deutsche Bank AG
Deutsche Bank AG increased its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 49.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 30,213 shares of the company’s stock after buying an additional 9,986 shares during the quarter. Deutsche Bank AG’s holdings in Phathom Pharmaceuticals were worth $245,000 at the end of the […] - 2025-06-02 04:42:48
Two Sigma Investments LP Has $3.95 Million Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Two Sigma Investments LP lifted its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 215.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 485,790 shares of the company’s stock after acquiring an additional 331,760 shares during the period. Two Sigma […] - 2025-05-29 05:14:54
Wells Fargo & Company MN Grows Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Wells Fargo & Company MN boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 41.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 25,516 shares of the company’s stock after purchasing an additional 7,462 shares during the quarter. Wells Fargo & Company MN’s holdings in Phathom Pharmaceuticals were worth $207,000 […] - 2025-05-09 04:16:49
Brokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $21.83
Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating […] - 2025-05-02 02:26:49
Raymond James Financial Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Raymond James Financial Inc. bought a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 455,837 shares of the company’s stock, valued at approximately $3,701,000. Other large investors also […] - 2025-04-28 05:05:16
Phathom Pharmaceuticals (NASDAQ:PHAT) Earns “Buy” Rating from Needham & Company LLC
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $28.00 price target on the stock. Several other analysts have also recently weighed in on the company. […] - 2025-04-23 03:13:04
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Consensus PT from Analysts
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to […] - 2025-04-09 03:10:49
Virtu Financial LLC Acquires New Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Virtu Financial LLC acquired a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 13,424 shares of the company’s stock, valued at approximately $109,000. Other institutional investors and hedge funds have also modified their holdings of the company. Intech Investment Management LLC acquired […] - 2025-03-31 04:45:00
Raymond James Financial Inc. Purchases Shares of 455,837 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Raymond James Financial Inc. acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 455,837 shares of the company’s stock, valued at approximately $3,701,000. Several other institutional investors […] - 2025-03-28 06:04:52
Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group
Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) had its price objective reduced by The Goldman Sachs Group from $18.00 to $12.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a neutral rating on the stock. A number of other research firms have also commented on PHAT. HC Wainwright reissued a […] - 2025-03-11 04:40:47
Los Angeles Capital Management LLC Takes $171,000 Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Los Angeles Capital Management LLC acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 21,070 shares of the company’s stock, valued at approximately $171,000. Other hedge funds and other institutional investors […] - 2025-03-06 08:56:59
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Cantor Fitzgerald
Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. A number of other analysts have also weighed in on PHAT. HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares […] - 2025-02-27 04:14:49
Phathom Pharmaceuticals (NASDAQ:PHAT) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald started coverage on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Friday morning, MarketBeat.com reports. The firm issued an overweight rating and a $23.00 target price on the stock. A number of other analysts have also commented on the stock. Needham & Company LLC reiterated a “buy” […] - 2025-02-17 04:59:03

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc PHAT holdings

DateNumber of PHAT Shares HeldBase Market Value of PHAT SharesLocal Market Value of PHAT SharesChange in PHAT Shares HeldChange in PHAT Base ValueCurrent Price per PHAT Share HeldPrevious Price per PHAT Share Held
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PHAT by Blackrock for IE00B3VWM098

Show aggregate share trades of PHAT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-05-23BUY1134.0204.220 4.200USD 475 7.15
2025-05-19SELL-1134.3904.485 4.476USD -506 7.24 Profit of 312 on sale
2025-05-15SELL-3393.4803.570 3.561USD -1,207 7.30 Profit of 1,266 on sale
2025-05-12SELL-2263.1503.394 3.370USD -762 7.40 Profit of 910 on sale
2025-04-30SELL-1134.2904.360 4.353USD -492 7.71 Profit of 379 on sale
2025-04-24SELL-2264.1204.167 4.162USD -941 7.84 Profit of 831 on sale
2025-04-17SELL-1134.0304.300 4.273USD -483 8.02 Profit of 424 on sale
2025-04-15SELL-3394.7705.090 5.058USD -1,715 8.09 Profit of 1,028 on sale
2025-04-14SELL-3394.6305.030 4.990USD -1,692 8.12 Profit of 1,063 on sale
2025-04-09SELL-4564.4304.570 4.556USD -2,078 8.24 Profit of 1,678 on sale
2025-04-07SELL-7984.8705.090 5.068USD -4,044 8.31 Profit of 2,588 on sale
2025-04-04SELL-1,1404.8805.050 5.033USD -5,738 8.35 Profit of 3,777 on sale
2025-03-31BUY1146.2706.660 6.621USD 755 8.43
2025-03-19SELL-2286.0806.160 6.152USD -1,403 8.63 Profit of 564 on sale
2025-03-14SELL-6844.4104.480 4.473USD -3,060 8.76 Profit of 2,933 on sale
2025-03-13SELL-2284.2205.050 4.967USD -1,132 8.82 Profit of 878 on sale
2025-03-12SELL-3,8765.0005.250 5.225USD -20,252 8.86 Profit of 14,107 on sale
2025-03-07SELL-2285.0605.770 5.699USD -1,299 9.02 Profit of 758 on sale
2025-03-06SELL-3425.9006.980 6.872USD -2,350 9.07 Profit of 750 on sale
2025-03-03SELL-1145.2105.910 5.840USD -666 9.21 Profit of 384 on sale
2025-02-28SELL-53,6485.5205.740 5.718USD -306,759 9.26 Profit of 189,947 on sale
2025-02-26SELL-2545.7906.180 6.141USD -1,560 9.36 Profit of 817 on sale
2025-02-25SELL-7655.5805.700 5.688USD -4,351 9.41 Profit of 2,850 on sale
2025-02-18BUY1,2705.7206.020 5.990USD 7,607 9.71
2025-02-13BUY2545.6205.815 5.796USD 1,472 9.91
2025-02-12BUY2545.4805.550 5.543USD 1,408 9.98
2025-02-11BUY7625.3905.520 5.507USD 4,196 10.06
2025-02-06BUY2,2865.9006.362 6.316USD 14,438 10.29
2025-01-27BUY2546.5607.010 6.965USD 1,769 10.97
2025-01-22SELL-5086.9907.100 7.089USD -3,601 11.24 Profit of 2,107 on sale
2025-01-17SELL-2546.9607.050 7.041USD -1,788 11.55 Profit of 1,144 on sale
2025-01-16BUY2546.9607.200 7.176USD 1,823 11.66
2025-01-14BUY7626.7906.830 6.826USD 5,201 11.90
2025-01-13BUY5086.6206.901 6.873USD 3,491 12.04
2025-01-08BUY1,5246.9507.190 7.166USD 10,921 12.47
2024-12-30BUY1,2708.0008.290 8.261USD 10,491 12.77
2024-12-06BUY1,0169.0009.010 9.009USD 9,153 13.13
2024-12-05BUY2548.5009.100 9.040USD 2,296 13.29
2024-12-04BUY1,2708.9509.030 9.022USD 11,458 13.45
2024-11-29BUY1,2708.8709.013 8.999USD 11,428 14.01
2024-11-27BUY1,0168.9709.110 9.096USD 9,242 14.44
2024-11-26BUY2538.9709.140 9.123USD 2,308 14.69
2024-11-21BUY1,2659.4509.620 9.603USD 12,148 15.55
2024-11-20BUY7598.7309.590 9.504USD 7,214 15.93
2024-11-18BUY3,0368.8909.100 9.079USD 27,564 16.77
2024-11-12BUY2,0249.52013.320 12.940USD 26,191 17.26
2024-11-08BUY1,26516.86019.045 18.827USD 23,816 17.29
2024-11-07BUY3,78018.50018.800 18.770USD 70,951 17.19
2024-11-06BUY50418.00019.050 18.945USD 9,548 17.13
2024-10-31BUY25217.15017.420 17.393USD 4,383 16.60
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PHAT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19139,3985,853238,44558.5%
2025-09-18231,5900435,92953.1%
2025-09-17125,198468331,18437.8%
2025-09-16113,3380340,75233.3%
2025-09-1590,16564234,11538.5%
2025-09-12169,773205333,83550.9%
2025-09-11143,186314355,54740.3%
2025-09-10155,225500265,37458.5%
2025-09-09202,0575,735503,03240.2%
2025-09-08217,7081,121543,52140.1%
2025-09-05159,010384511,09331.1%
2025-09-04190,6150634,47030.0%
2025-09-03426,1056510,09883.5%
2025-09-02249,80830382,10665.4%
2025-08-29109,125197266,15941.0%
2025-08-28204,11370246,32182.9%
2025-08-27260,734100432,38560.3%
2025-08-26315,3490632,31049.9%
2025-08-25174,5740349,82649.9%
2025-08-22513,8913,825921,39455.8%
2025-08-21356,1481,600459,38677.5%
2025-08-20311,3971385,89780.7%
2025-08-19224,9051,165319,61570.4%
2025-08-18142,7301,000269,66052.9%
2025-08-15239,8851,098370,15564.8%
2025-08-14262,83961346,86275.8%
2025-08-13306,9544,839506,13660.6%
2025-08-12243,2222,486347,57870.0%
2025-08-11315,783901596,32853.0%
2025-08-08312,0411,001566,25655.1%
2025-08-07497,7302,9291,034,13748.1%
2025-08-06468,636321545,06586.0%
2025-08-05131,901120194,84967.7%
2025-08-04115,3150201,09657.3%
2025-08-01102,2200202,25050.5%
2025-07-31123,2940229,81553.6%
2025-07-30201,5940302,35666.7%
2025-07-29261,6380412,61063.4%
2025-07-28341,149600475,15971.8%
2025-07-25627,57312,209906,29069.2%
2025-07-24259,8680546,21347.6%
2025-07-23158,6140393,14740.3%
2025-07-22150,0620232,81664.5%
2025-07-21153,117500241,06263.5%
2025-07-18194,5311,111337,90157.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy